BTIG analyst Ryan Zimmerman maintained a Buy rating on Humacyte (HUMA – Research Report) yesterday and set a price target of $8.00. The company’s shares closed last Friday at $2.84.
Zimmerman covers the Healthcare sector, focusing on stocks such as Glaukos, Vericel, and Stryker. According to TipRanks, Zimmerman has an average return of 8.9% and a 47.46% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Humacyte with a $7.00 average price target, representing a 146.48% upside. In a report released on December 27, Benchmark Co. also maintained a Buy rating on the stock with a $15.00 price target.
See the top stocks recommended by analysts >>
Based on Humacyte’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $26 million. In comparison, last year the company earned a revenue of $31 thousand and had a GAAP net loss of $25.28 million
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HUMA in relation to earlier this year. Most recently, in November 2023, Wallace Max N., a Director at HUMA bought 6,564.00 shares for a total of $7,811.16.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Humacyte (HUMA) Company Description:
Alpha Healthcare Acquisition Corp is a blank check company.
Read More on HUMA:
- Humacyte price target lowered to $15 from $16 at Benchmark
- 2 Best Stocks to Buy Now, 13/12/2023, According to Top Analysts
- Humacyte submits BLA to U.S. FDA seeking approval of HAV
- Humacyte initiated with bullish view at H.C. Wainwright, here’s why
- Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference
